Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.2552W HIGH $41.80
Volume
22.71 K
Value Traded
114.13 K
Short % Float
-
-2.46%Week
-37.45%1 Month
-2.02%3 Month
-26.1%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.54 M
EPS (TTM)
-9.29
P/E Ratio
-
Ent. Value
-2.26 M
Total Shares
2.01 M
Float Shares
-
Insiders
-
Institutions
70.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
QNRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Quoin Pharmaceuticals, Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quoin Pharmaceuticals, Ltd.
459Total events
15Upcoming
110Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲PublicationQRX003Presentation
Manuscript on QRX003 mechanism and pediatric compassionate-use case report accepted for publication in Dermatology and Therapy
Netherton Syndromesource ↗
▲Additional DataQRX003Clinical Data
Case report of pediatric patient treated with QRX003 under compassionate use showing fully healed skin and elimination of pruritus
Netherton Syndromesource ↗
▲Fast Track DesignationQRX003Designation
FDA grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
▲Rare Pediatric DiseaseQRX003Designation
FDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
▲Interim AnalysisQRX003Trial
Positive interim analysis of first six patients in Phase 2/3 study of QRX003
Netherton Syndromesource ↗
▲Topline ReadoutQRX003Clinical Data
Positive interim clinical data released from ongoing Phase 2/3 study of QRX003 in Netherton Syndrome
Netherton Syndromesource ↗
▲Primary Endpoint MetQRX003Clinical Data
Four of six (66.7%) achieved primary endpoint of 1-grade or greater improvement in Investigator Global Assessment (p=0.0087)
Netherton Syndromesource ↗
▲Interim Efficacy DataQRX003Clinical Data
Positive interim results from Phase 2/3 study CL-QRX003-004 of QRX003 4% lotion in Netherton Syndrome
Netherton Syndromesource ↗
▲IND ClearanceQRX003IND
FDA cleared IND for Peeling Skin Syndrome with no safety concerns
Peeling Skin Syndromesource ↗
●IND SubmissionQRX009IND
Submit IND to FDA for QRX009 for an additional indication
additional indication (not specified)source ↗
◆Topline ReadoutQRX003Clinical Data
Top-line data anticipated from two pivotal trials
Netherton Syndromesource ↗
▲IND ClearanceQRX003IND
FDA clearance of IND for QRX003 in Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
▲Patent GrantedQRX003IP / Competition
USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome
Netherton Syndromesource ↗
▲FDA Feedback ReceivedQRX003FDA Meeting
FDA conditionally approved QYLEKI as proposed brand name for QRX003
Netherton Syndromesource ↗
▲Other Regulator MilestoneQRX003Ex-US Regulatory
Establishment of Japanese subsidiary for commercial readiness
Netherton Syndromesource ↗
▲Orphan Drug DesignationQRX003Designation
Orphan Drug Designation granted by Japan's MHLW
Netherton Syndromesource ↗
▲Enrollment UpdateQRX003Trial
Six pediatric patients enrolled in compassionate use program
Netherton Syndromesource ↗
▲Topline ReadoutQRX003Clinical Data
Positive clinical update: 4 of 6 patients improved or significantly improved
Netherton Syndromesource ↗
▲Safety Data UpdateQRX003Clinical Data
Positive clinical update from ongoing Pediatric Compassionate Use Program
Netherton Syndromesource ↗
▲Enrollment UpdateQRX003Trial
Additional pediatric patient enrolled on June 15, 2026
Netherton Syndromesource ↗
▲Other Regulator MilestoneQRX003Ex-US Regulatory
Japan MHLW grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Netherton Syndromesource ↗
●IND SubmissionQRX003IND
Quoin submits IND for QRX003 in Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
▲Enrollment UpdateQRX003Trial
Four of six pediatric patients in Compassionate Use Program classified as Improved or Significantly Improved
Netherton Syndromesource ↗
▲Additional DataQRX003Clinical Data
Four of six pediatric patients in Compassionate Use Program classified as Improved or Significantly Improved
Netherton Syndromesource ↗
●IND SubmissionQRX003IND
Target IND application for Peeling Skin Syndrome
Peeling Skin Syndromesource ↗
◆Topline ReadoutQRX003Clinical Data
Anticipates reporting topline data from two whole-body clinical trials for QRX003 in Netherton Syndrome
Netherton Syndromesource ↗
●Trial InitiationTrial
Initiate proof of concept clinical testing of topical rapamycin platforms in at least one indication
◆Breakthrough Therapy DesignationQRX003Designation
Potential accelerated regulatory review and availability in Saudi Arabia if Breakthrough Medicine Designation granted
Netherton Syndromesource ↗
▲Type C MeetingQRX003FDA Meeting
Constructive Type C meeting with FDA; FDA indicated single Phase 3 study may be sufficient for marketing approval, open to alternative study design
Netherton Syndromesource ↗
▲Fast Track DesignationQRX003Designation
FDA grants Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome
Netherton Syndromesource ↗
▲Quarterly UpdateCorporate
NETHERTON NOW campaign generated nearly 2 million video views and more than 24 million impressions globally
▲Fast Track DesignationQRX003Designation
U.S. FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome
Netherton Syndromesource ↗
▲Type C MeetingQRX003FDA Meeting
Constructive Type C meeting with FDA for QRX003; FDA indicated single Phase 3 study may suffice
Netherton Syndromesource ↗
▲PRV GrantedDesignation
Rare Pediatric Disease PRV program extended by Congress through September 30, 2029
▲Fast Track DesignationQRX003Designation
MHLW confirmed QRX003 qualifies for Fast Track regulatory review in Japan
Netherton Syndromesource ↗
◆Other Regulator MilestoneQRX003Ex-US Regulatory
Submitted application for Orphan Drug Designation to Japanese MHLW
Netherton Syndromesource ↗
▲Fast Track DesignationQRX003Designation
Submitted application to Japan's MHLW seeking Orphan Drug Designation for QRX003; MHLW confirmed eligibility for Orphan Drug Designation and Fast Track review
Netherton Syndromesource ↗
◆Orphan Drug DesignationQRX003Designation
Submitted Orphan Drug Designation application to Japanese MHLW for QRX003
Netherton Syndromesource ↗
◆Other Regulator MilestoneQRX003Ex-US Regulatory
Filed Breakthrough Medicine Designation application with Saudi FDA for QRX003
Netherton Syndromesource ↗
●Breakthrough Therapy DesignationQRX003Designation
Filed application for Breakthrough Medicine Designation with Saudi FDA for QRX003
Netherton Syndromesource ↗
◆Enrollment CompleteQRX003Trial
Full enrollment expected in early to mid-Q1 2026
Netherton Syndromesource ↗
▲Manufacturing Milestonetopical rapamycinCMC / Inspection
Achieved target loading of 4% rapamycin in topical lotion and 5% in dermal patch
▲Orphan Drug DesignationQRX003Designation
Orphan Drug Designation awarded by FDA to QRX003 for Netherton Syndrome
Netherton Syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How QNRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 63%
Micro Cap(rank 415 of 658)
Percentile Rank
Quoin Pharmaceuticals, Ltd. faces pipeline headwinds (32/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| QRX003 Small moleculeNCT05521438 | Netherton Syndrome | Phase 2 | ACTIVE NOT_RECRUITING | 74 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every QNRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| QRX003 Fast TrackOrphanRare Pediatric | Netherton Syndrome | Phase 2/3 | 2026-10-06 | four of six (66.7%) achieved the primary endpoint (p=0.0087 vs. a pre-specified alpha of 0.0215)Read More | Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Carter Denise P.Director, Officer (Chief Operating Officer) | Buy | 20,490 37,709 held | $4.88 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QNRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % | 352.00 K | 72.73 K | 190.92% ( 47.73 K) |
QNRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QNRX ranks across every disease it competes in
Competitive Position is a premium feature
See how QNRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQNRX News
QNRX▼ -6.6%today
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Quoin Pharmaceuticals announced the acceptance of a manuscript detailing QRX003, an investigational treatment for Netherton Syndrome, in a peer-reviewed journal. The paper includes a case report of a pediatric patient who experienced significant improvements under a compassionate use program. Interim results from a Phase 2/3 study also indicate positive outcomes for patients treated with QRX003.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin Pharmaceuticals has received FDA Fast Track Designation for QRX003, a treatment for Peeling Skin Syndrome, marking a significant milestone as it is the first therapy to receive such designation for this condition. The designation follows the clearance of an Investigational New Drug application and supports the planned Phase 2/3 clinical study expected to start in the second half of 2026. QRX003 aims to address a critical unmet medical need, as there are currently no approved treatments for Peeling Skin Syndrome.
Read more →QNRXQuoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
Quoin Pharmaceuticals has released a new episode of its NETHERTON NOW video series featuring Aminah, a child with Netherton Syndrome, and her adoptive mother, Dr. Laura Wright-Sexton. The video showcases Aminah's significant progress since her adoption and the challenges faced by families dealing with rare diseases. Quoin's investigational product QRX003 is currently in a Phase 2/3 clinical trial for treating Netherton Syndrome.
Read more →QNRXQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has received FDA Rare Pediatric Disease Designation for QRX003, aimed at treating Peeling Skin Syndrome. This designation could lead to two Priority Review Vouchers if a New Drug Application is approved. Quoin plans to initiate a Phase 2 study by the end of 2026, enrolling up to 12 patients in the U.S. and Europe. Currently, there are no approved treatments for this condition.
Read more →QNRX▲ +18.7%on this news
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
Quoin Pharmaceuticals has announced a private placement financing of up to $50 million, which includes $30.8 million in upfront funding. The financing aims to support the development of QRX003 for Netherton Syndrome and other corporate purposes. The deal involves participation from several institutional investors and is expected to close by August 31, 2026.
Read more →QNRX▲ +18.7%on this news
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Quoin Pharmaceuticals announced positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. The study showed that 66.7% of participants achieved a significant improvement in the primary endpoint after 12 weeks of treatment. Additionally, key secondary endpoints also met statistical significance, and no serious adverse events were reported. The company expects to complete participant recruitment by the end of 2026.
Read more →QNRX▼ -15.9%on this news
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals reported significant corporate advancements in Q2 2026, including FDA conditional approval for the brand name QYLEKI™ for QRX003, aimed at treating Netherton Syndrome. The company also received a Notice of Allowance for a patent covering a combination treatment for the same condition. Additionally, Quoin submitted the first-ever IND for Peeling Skin Syndrome, with plans for a Phase 2/3 study to begin in the latter half of 2026.
Read more →QNRXQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
Quoin Pharmaceuticals Ltd. plans to announce a corporate update and financial results for Q2 2026 on August 14, 2026. The announcement will include operational highlights and key achievements from the quarter. The company specializes in developing treatments for rare and orphan diseases, with a focus on products like QRX003 and QRX009.
Read more →QNRXQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has received FDA IND clearance to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome, expected to start in the second half of 2026. This marks the first formal clinical study for this condition, which currently has no approved treatments. The study aims to enroll 6-8 patients in the U.S. and Europe, with a focus on developing a much-needed therapy.
Read more →QNRX▲ +6.4%on this news
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Quoin Pharmaceuticals has received a Notice of Allowance from the USPTO for a patent covering a combination treatment for Netherton Syndrome. This patent supports their investigational drug QRX003, which could become the first approved treatment for this rare genetic skin disease. The allowed claims include treatment methods for patients with SPINK5 mutations, enhancing Quoin's intellectual property position.
Read more →QNRX▼ -26.3%on this news
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Quoin Pharmaceuticals has received conditional FDA approval for the brand name QYLEKI for QRX003, its investigational treatment for Netherton Syndrome. This marks a significant milestone as the company prepares for a pivotal Phase 3 study expected to start in late 2026, with a potential NDA filing in 2027. QRX003 has received Orphan Drug and Fast Track designations, indicating strong regulatory support.
Read more →QNRXQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Quoin Pharmaceuticals has established a wholly-owned subsidiary in Japan to facilitate the direct commercialization of QRX003, aimed at treating Netherton Syndrome. This move follows the recent Orphan Drug Designation granted by Japan's MHLW. Quoin's strategy includes building commercial infrastructure in Japan, which is one of its three core markets, alongside the U.S. and Western Europe.
Read more →QNRXQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Quoin Pharmaceuticals has provided a positive clinical update on its Compassionate Use program for pediatric Netherton Syndrome, with four out of six patients showing improvements across key clinical endpoints. The youngest participant, only 6 months old, saw significant benefits after just three weeks of treatment. No adverse events related to the treatment were reported, emphasizing the safety of their product, QRX003. Quoin aims to enroll additional patients and will release comprehensive data from the program in the coming months.
Read more →QNRXQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals has announced that Japan's MHLW has granted Orphan Drug Designation for QRX003, aimed at treating Netherton Syndrome. This designation offers significant regulatory incentives, including market exclusivity upon approval. Quoin has already received similar recognitions from the U.S. FDA and the European Medicines Agency. The company is currently fine-tuning its clinical and regulatory paths in collaboration with Japanese clinicians, aiming to start pivotal Phase 3 trials later in 2026.
Read more →QNRXQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals has submitted an IND application for QRX003 to treat Peeling Skin Syndrome, marking a significant milestone as it is the first submission for this disease. The application is backed by positive results from an ongoing pediatric study. Quoin plans to initiate a Phase 2 clinical study in the second half of 2026, recruiting patients in the US and Europe.
Read more →QNRXQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
Quoin Pharmaceuticals announced significant progress in its regulatory activities regarding QRX003 for Netherton Syndrome. The company filed for Breakthrough Medicine Designation with the Saudi FDA and received Fast Track Designation from the U.S. FDA, with indications that a single Phase 3 study may be sufficient for marketing approval. Quoin is also on track for an NDA filing in 2027. Furthermore, the company saw an increase in net loss for Q1 2026 compared to the same period in the previous year, highlighting potential financial challenges.
Read more →QNRX▲ +9.3%on this news
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
Quoin Pharmaceuticals Ltd. plans to announce a corporate update and its financial results for Q1 2026 on May 7, 2026. The announcement will include operational highlights and financial achievements. Quoin specializes in developing therapies for rare diseases, with a focus on two main products, QRX003 and QRX009.
Read more →QNRXCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Quoin Pharmaceuticals announced a clinical and regulatory update for its QRX009 topical rapamycin programs. The company plans to initiate several investigator-led studies, starting with Pachyonychia Congenita, led by Professor Edel O'Toole. Additionally, Quoin aims to submit an Investigational New Drug Application to the FDA for QRX009 by Q3 2026, targeting multiple indications.
Read more →QNRXQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Quoin Pharmaceuticals announced an update on its development programs for QRX009, a topical rapamycin designed for rare skin diseases. The company plans to initiate several investigator-led clinical studies targeting Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. Notably, the study on Pachyonychia Congenita will be led by renowned expert Professor Edel O'Toole. Additionally, Quoin aims to submit an Investigational New Drug Application to the FDA for QRX009 for another indication, with multiple studies expected to commence by the end of 2026.
Read more →QNRX▼ -18.4%on this news· ran to -31% by day 1
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Quoin Pharmaceuticals reported significant advancements in its corporate update for Q4 and full-year 2025. The company secured Orphan Drug Designations for QRX003 for Netherton Syndrome in both the U.S. and Europe and closed a private placement financing of up to $104.5 million. Clinical studies for QRX003 show promising long-term efficacy and safety, with plans for further expansion and regulatory submissions in 2026.
Read more →About Quoin Pharmaceuticals, Ltd.
Headquarters23 HATA'AS STREET, KFAR SABA, 44425
BIOPHARMAWATCH ELITE PLUS
Trade the next QNRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime